Wild Type Transthyretin Amyloidosis (ATTRwt): An Overview | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Patient Education

Wild Type Transthyretin Amyloidosis (ATTRwt): An Overview

key information

source: Amyloidosis Foundation

year: 2018

summary/abstract:

Wild-type ATTR is also referred to as ATTRwt. It is not hereditary. This disease used to be called SSA, which stood for Senile Systemic Amyloidosis, which is now an outdated term. Deposits of TTR amyloid can be found throughout the body, so it is a systemic amyloidosis disease, with significant clinical involvement most commonly found in the heart. Wild-type ATTR is also common in carpal tunnel, which can be the first (early) symptom.

This is a disease that is almost exclusively a disease of men, originally reported in those age of 80 and over. As research continues, wild-type ATTR has been increasingly found in individuals in their early 60s. It is often overlooked as an amyloidosis disease because so many people experience heart problems in their later years.

It is called wild-type ATTR because the misfolding and depositing amyloid protein comes from transthyretin protein without a genetic mutation, referred to as “wild-type” because it is the natural form of this protein. These deposits can interfere with the heart’s normal function, causing heart rhythm problems and heart failure.

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close